AbbVie Inc. ABBV
AbbVie Inc. (NYSE: ABBV) is an immunology/inflammation drug developer. Its lead program, Rinvoq (upadacitinib), is in Phase 3 for multiple immune-mediated diseases (new submissions: non-segmental vitiligo, severe alopecia areata).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| Skyrizi (risankizumab) | Crohn's disease subcutaneous induction (new submission) | antibody | Approved |
| Rinvoq (upadacitinib) | non-segmental vitiligo; severe alopecia areata (applications submitted) | small molecule | Approved |
| Decnupaz (pivekimab sunirine-pvzy) | BPDCN | antibody | Approved |
| trenibotulinumtoxinE | moderate to severe glabellar lines | protein/peptide | Phase 3 |
| ABBV-706 | R/R small cell lung cancer | antibody | Phase 3 |
| Temab-A | refractory metastatic colorectal cancer | antibody | Phase 3 |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 3 immunology/inflammation companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.